Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Corsair Pharma logo — Pulmonary Arterial Hypertension

Corsair Pharma

Pulmonary Arterial Hypertension

Founded 2014 United States Sunnyvale, United States 11 employees Series B Total: $23.00M Health Care, Health and Wellness +1

General Information

Company Name Corsair Pharma
Founded Year 2014
Location United States Sunnyvale, United States
Employees 11
Industries Health Care, Health and Wellness, Manufacturing
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Corsair Pharma. To contact Corsair Pharma, visit corsairpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Corsair Pharma

Corsair Pharma is a manufacturing startup that focuses on developing innovative solutions to enhance the therapeutic efficacy of medications, particularly targeting Pulmonary Arterial Hypertension (PAH). Founded in 2014 and headquartered in the United States, the company has garnered significant attention in the industry. Its recent achievement includes securing a substantial $23.00M Series B investment on 20 September 2023. Notably, the investment was led by a consortium of prominent investors including New Rhein Healthcare Investors, Primavera Capital, Junson Capital, Midas Capital, and Plaisance Capital Management. Corsair Pharma's commitment to developing novel prodrugs of treprostinil, with a focus on a once-daily transdermal patch for PAH patients, signifies its dedication to introducing superior treatment options for this patient population. With this injection of capital, the company is poised to further its research and development efforts, potentially revolutionizing the treatment landscape for individuals battling PAH. Attracting a diverse range of globally recognized investors is a testament to the promise and potential of Corsair Pharma's transformative solutions, reflecting a high degree of confidence in the company's vision and strategies.

Taxonomy: Pharmaceuticals, Drug Development, Prodrugs, Pulmonary Arterial Hypertension, Therapeutic Solutions, Transdermal Patch, Treatment Innovation, Medical Research, PAH Therapy, Patient-Centric Care

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $23.00M 5
New Rhein Healthcare Investors Primavera Capital
New Rhein Healthcare Investors, Primavera Capital +3
20 Sep 2023

Corsair Pharma Alternatives & Competitors

View All Alternatives
Corsair Pharma vs
Respira Therapeutics, Inc.
Respira Therapeutics, Inc. United States

Improving patient outcomes through enhanced drug targeting to the lung

Series B
19 employees
Health Care, Health and Wellness
Corsair Pharma vs
Sumitomo Pharma Oncology
Sumitomo Pharma Oncology United States

is part of Sumitomo Pharma America as of July 2023

49 employees
Health Care, Health and Wellness
Corsair Pharma vs
Gossamer Bio
Gossamer Bio United States

Vision * Connection * Innovation

Post-IPO Equity
159 employees
Biotechnology, Health Care
View all alternatives

FAQ About Corsair Pharma

Pulmonary Arterial Hypertension
Corsair Pharma was founded in 2014.
Corsair Pharma is headquartered in Sunnyvale, United States.
Corsair Pharma operates in Health Care, Health and Wellness and Manufacturing. Its work centres on Pharmaceuticals, Drug Development, Prodrugs and Pulmonary Arterial Hypertension.
Corsair Pharma has approximately 11 employees.
Corsair Pharma has completed 1 funding round, raising a total of $23.00M. The latest funding stage is Series B.
Top alternatives and competitors to Corsair Pharma include Respira Therapeutics, Inc., Sumitomo Pharma Oncology, Gossamer Bio, NewLink Genetics, Crinetics Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Corsair Pharma and Respira Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Corsair Pharma, https://bouncewatch.com/company/corsair-pharma, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes